Venus Remedies Profit & Loss Annual

BSE: 526953 | NSE: VENUSREM | ISIN: INE411B01019 | Sector: Biotechnology & Drugs

299.90 +7.85 (2.69%)Updated : 25 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Revenue	601.45	555.51	598.65	548.12
Total Revenue	601.45	555.51	598.65	548.12
Costof Revenue Total	354.69	343.17	385.45	340.79
Gross Profit	246.76	212.34	213.20	207.33
Selling/ General/ Admin Expenses Total	171.32	129.25	128.05	137.80
Research Development	158.40	228.85	230.30	157.58
Depreciation/ Amortization	26.44	32.30	33.53	35.28
Total Operating Expense	568.29	527.12	569.61	506.18
Operating Income	33.16	28.39	29.04	41.94
Interest Inc( Exp) Net- Non- Op Total	-0.90	90.71	5.13	-70.10
Other Net	11.58	0.47	6.85	13.62
Net Income Before Taxes	44.65	37.93	36.41	48.55
Provisionfor Income Taxes	16.15	11.36	-4.32	-13.21
Net Income After Taxes	28.50	26.57	40.72	61.77
Net Income Before Extra Items	28.50	26.57	40.72	61.77
Net Income	28.50	26.57	40.72	61.77
Total Adjustmentsto Net Income	-0.10	-	-	-
Income Availableto Com Excl Extra Ord	28.49	26.57	40.72	61.77
Income Availableto Com Incl Extra Ord	28.49	26.57	40.72	61.77
Diluted Net Income	28.49	26.57	40.72	61.77
Diluted Weighted Average Shares	1.35	1.34	1.32	1.23
Diluted EPS Excluding Extra Ord Items	21.13	19.87	30.86	50.04
Diluted Normalized EPS	21.13	19.87	30.86	37.70
Other Operating Expenses Total	-	-0.49	-0.46	-
Unusual Expense( Income)	-	-	0.00	-23.44